ClinicalTrials.gg
RecruitingNCT07782593SMARTEATS-RCTUpdated Oct 13, 2026

Satiety, Microbiome, Appetite Regulation, and Tracking Energy Across Targeted Snacks: Chronic Study

An interventional study of High-fibre plant-based snack bar and Control snack bars in Healthy Participants, Healthy Adult Subject and Healthy Subjects, sponsored by Zoe Global Limited. Recruiting at 1 site in United Kingdom. Open to participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Zoe Global Limited · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
35 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn how eating different snack foods affects long term hunger and gut health in healthy adults. The study will be conducted remotely over 7 weeks.

The main questions it aims to answer are:

  1. Does eating a snack bar intervention for 5-weeks change how hungry participants feel throughout the day compared to a control?
  2. Does eating a snack bar intervention change gut microbiome, bowel habits, digestive symptoms, and other health measures compared to a control over 5 weeks?

Researchers will compare an intervention snack bar to a control snack bar to see if the intervention improves hunger, gut microbiome, digestive symptoms and other health measures.

Participants will:

  • Eat 2 snack bars in place of their usual snacks every day for 4 weeks
  • Complete health measurements at the start and end of the study: a health questionnaire, 3-day food diary, 3-day hunger \& satiety survey, body measurements, and a stool sample
  • Fill out a short online survey (under 5 minutes) once a week
Read the detailed description

Diet, and snacking behaviour in particular, plays an important role in long-term health. Snacking now contributes substantially to daily energy intake in the UK and US: data from the ZOE PREDICT study show that 95% of adults snack at least once a day, with snacks accounting for around a quarter of daily energy intake (2.28 snacks/day). However, the average UK snack has a poor nutrient profile, high in refined carbohydrates, added sugars, and saturated fat, and low in fibre and micronutrients, a pattern linked to poorer cardiometabolic health. Despite public health guidance to consume at least 30g of fibre a day, UK adults consume an average of around 20g/day. However, the composition and timing of a snack are important determinants of its effects on hunger, energy, and other health markers.

This trial evaluates an intervention (2 x snack bars) against a control (2 x snack bars that reflect the average nutrient profile of snacks currently sold in the UK). Using a control snack bar means any effects observed can be attributed to the specific formulation of the intervention snack bar, rather than simply to a change in snacking habits or a reduction in overall snack consumption.

The primary aim of the study is to determine whether the intervention snack bars reduce subjective daily hunger over 5 weeks of daily use, compared with control snack bars representative of the average UK snack nutrient profile. The study will be conducted in 2 phases. In this phase (phase 2; chronic randomised controlled trial), 100 participants (50 per arm) will eat the intervention or control bars daily for 5 weeks. Secondary aims for this phase include the bar's effects on gut microbiome composition, gastrointestinal symptoms, bowel habits (frequency and consistency), subjective mood and energy, sleep quality, and anthropometric measures. The design allows the chronic effects of the intervention snack bars to be assessed when the bars are eaten regularly in place of habitual snack foods.

02

Conditions studied

  • Healthy Participants
  • Healthy Adult Subject
  • Healthy Subjects
  • Healthy Adult Volunteer
  • Healthy Adult Participants

Keywords

  • Snacks
  • Snack foods
  • Dietary intervention
  • Hunger
  • Health
  • Wellbeing
  • Nutrition study
  • Microbiome
03

In context

Lead sponsor

Zoe Global Limited is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to follow the study protocol
  • Willing and able to provide
  • Regular consumption of snacks (≥2 per day)
  • Fibre intake \<20 g/d
  • Living in the UK

Exclusion criteria

Exclusion Criteria:

  • Have of less than 18.5 kg/m² or more than 40 kg/m²
  • Have an allergy or intolerance to ingredients in the intervention or control snack bars (including inulin) or cannot eat the food products safely and comfortably for any reason
  • Have a personal medical history of inflammatory bowel disease, coeliac disease, Crohn's disease, irritable bowel syndrome, chronic constipation, or chronic diarrhoea
  • Have started a new supplement in the past month, or are unwilling to maintain current supplement use throughout the study
  • Previously purchased any ZOE products (including Daily30, ZOE gut health bar or ZOE app membership).
  • Have taken any medication or product that may modify the measured study outcomes, in the past 3 months (including but not limited to: fibre supplements, antibiotics, non-topical or other medicines, probiotics or prebiotics, metformin, GLP-1 receptor agonists, lipid-lowering medications such as fibrates, statins, PCSK9 inhibitors, non-steroidal anti-inflammatory drugs)
  • Have used opiate pain medication or a proton pump inhibitor for 8 or more consecutive days during the past 3 months
  • Have experienced a heart attack, stroke or major surgery in the last 2 months
  • Have received treatment for cancer in the last 3 months
  • Are currently pregnant, breastfeeding or planning a pregnancy
  • Are diagnosed with an eating disorder, type 1 diabetes mellitus or type 2 diabetes mellitus
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Intervention

    Snack intervention (2x snack bars). To be eaten instead of regular snacks twice a day for 5 weeks.

    Other: High-fibre plant-based snack bar

  • Placebo comparator
    Control

    Control snack (2x snack bars). To be eaten instead of regular snacks twice a day for 5 weeks.

    Other: Control snack bars

Interventions

  • OtherHigh-fibre plant-based snack bar

    High-fibre plant-based snack bars.

  • OtherControl snack bars

    Commercially available snack bars (UK); reflects the energy and macronutrient profile of a typical UK snack.

06

What researchers measure

Primary outcomes

  1. Daily hunger

    Subjective hunger ratings, assessed using digital visual analogue scales (VAS; 0-100), with anchor points 0 = 'not at all hungry', 100 = 'extremely hungry'.

    Time frame: 2-hourly intervals for 3 days, at baseline and week 5 of the intervention.

Secondary outcomes

  1. Microbiome composition

    Relative abundance of selected microbiome species (those included in the ZOE microbiome-health ranks 2025 \& ZOE microbiome-diet ranks 2025), derived from metagenomic analysis of stool samples.

    Time frame: Baseline, week 5 of the intervention.

  2. Weight

    Self-reported body weight (kg).

    Time frame: Baseline, week 5 of the intervention.

  3. Body mass index (BMI)

    BMI (kg/m2) calculated from self-reported body weight (kg) and height (cm).

    Time frame: Baseline, week 5 of the intervention.

  4. Waist & Hip circumference

    Self-reported waist and hip circumference (cm).

    Time frame: Baseline, week 5 of the intervention.

  5. Gastrointestinal symptoms

    Subjective gastrointestinal symptoms, assessed using the Gastrointestinal Symptoms Ratings Scale. Participants rate symptoms on a 7-point scale ranging from 'no discomfort' to 'severe discomfort'.

    Time frame: Baseline, week 5 of the intervention.

  6. Stool frequency

    Self-reported stool frequency (bowel movements per week) assessed via online questionnaire.

    Time frame: Baseline, week 5 of the intervention.

  7. Stool consistency

    Self-reported stool consistency assessed via the Bristol Stool Form Scale. Participants rate their average stool consistency on a 7-point scale.

    Time frame: Baseline, week 5 of the intervention.

  8. Satiety

    Subjective satiety ratings, assessed using digital visual analogue scales (VAS; 0-100), with anchor points 0 = 'not at all', 100 = 'extremely'.

    Time frame: Baseline (3-days), week 5 of the intervention (3-days)

  9. Subjective energy, mood & alertness

    Subjective ratings of energy, mood and alertness, assessed using digital visual analogue scales (VAS; 0-100), with anchor points 0 = 'not at all', 100 = 'extremely'.

    Time frame: Baseline (3-days), week 5 of the intervention (3-days)

  10. Sleep

    Self-reported sleep quality, assessed using the Pittsburgh Sleep Quality Index. Scores range from 0-6, with higher scores indicating poor sleep quality.

    Time frame: Baseline, week 5 of the intervention.

  11. Energy and nutrient intake

    Energy (kcal) and nutrient intake (g/day; %EI), assessed using digital food log (myFood24).

    Time frame: Baseline (3-days), week 5 of the intervention (3-days).

Other outcomes

  1. Treatment acceptability

    Acceptability of intervention and control treatments, assessed via online questionnaire at endpoint.

    Time frame: Week 5 of the intervention.

  2. Microbiome composition

    Relative abundance of selected microbiome species (those included in the ZOE microbiome-health ranks 2025 \& ZOE microbiome-diet ranks 2025), derived from metagenomic analysis of stool samples. Measured in a sub-group of participants (approx. n = 20) to determine whether there are detectable changes in the gut microbiome following a short term (2-3 weeks) dietary intervention.

    Time frame: Week 3 of the intervention (midpoint)

07

Study locations

1 of 1 sites recruiting
  • ZOE limited
    London, United Kingdom
    Recruiting
08

References and documents

Publications

  • Brown R, Ware L, Gray AR, Chisholm A, Tey SL. Snacking on Almonds Lowers Glycaemia and Energy Intake Compared to a Popular High-Carbohydrate Snack Food: An Acute Randomised Crossover Study. Int J Environ Res Public Health. 2021 Oct 19;18(20):10989. doi: 10.3390/ijerph182010989. PubMed 34682735 ↗
  • Kikuchi H, Yoshiuchi K, Inada S, Ando T, Yamamoto Y. Development of an ecological momentary assessment scale for appetite. Biopsychosoc Med. 2015 Jan 15;9(1):2. doi: 10.1186/s13030-014-0029-6. eCollection 2015. PubMed 25614760 ↗
  • Scheer FA, Morris CJ, Shea SA. The internal circadian clock increases hunger and appetite in the evening independent of food intake and other behaviors. Obesity (Silver Spring). 2013 Mar;21(3):421-3. doi: 10.1002/oby.20351. PubMed 23456944 ↗
  • Beaulieu K, Oustric P, Alkahtani S, Alhussain M, Pedersen H, Quist JS, Faerch K, Finlayson G. Impact of Meal Timing and Chronotype on Food Reward and Appetite Control in Young Adults. Nutrients. 2020 May 22;12(5):1506. doi: 10.3390/nu12051506. PubMed 32455860 ↗
  • Cheon E, Mattes RD. Interindividual variability in appetitive sensations and relationships between appetitive sensations and energy intake. Int J Obes (Lond). 2024 Apr;48(4):477-485. doi: 10.1038/s41366-023-01436-9. Epub 2023 Dec 22. PubMed 38135701 ↗
  • Elsworth RL, Hinton EC, Flynn AN, Merrell LH, Hamilton-Shield JP, Lawrence NS, Brunstrom JM. Development of Momentary Appetite Capture (MAC): A versatile tool for monitoring appetite over long periods. Appetite. 2024 Mar 1;194:107154. doi: 10.1016/j.appet.2023.107154. Epub 2023 Dec 9. PubMed 38081544 ↗
  • Zhu Y, Blundell JE, Holschuh NM, McLean R, Menon RS. Validation of a Mobile App-Based Visual Analog Scale for Appetite Measurement in the Real World: A Randomized Digital Clinical Trial. Nutrients. 2023 Jan 7;15(2):304. doi: 10.3390/nu15020304. PubMed 36678176 ↗
  • Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48. doi: 10.1038/sj.ijo.0801083. PubMed 10702749 ↗
  • Godwin N, Roberts T, Hooshmand S, Kern M, Hong MY. Mixed Nuts May Promote Satiety While Maintaining Stable Blood Glucose and Insulin in Healthy, Obese, and Overweight Adults in a Two-Arm Randomized Controlled Trial. J Med Food. 2019 Apr;22(4):427-432. doi: 10.1089/jmf.2018.0127. Epub 2019 Mar 21. PubMed 30897012 ↗
  • Bermingham KM, May A, Asnicar F, Capdevila J, Leeming ER, Franks PW, Valdes AM, Wolf J, Hadjigeorgiou G, Delahanty LM, Segata N, Spector TD, Berry SE. Snack quality and snack timing are associated with cardiometabolic blood markers: the ZOE PREDICT study. Eur J Nutr. 2024 Feb;63(1):121-133. doi: 10.1007/s00394-023-03241-6. Epub 2023 Sep 15. PubMed 37709944 ↗

Individual participant data

Plan to share: Yes — To protect participant privacy, individual participant clinical data and any data that could be used to identify individuals will not be publicly available and cannot be deposited in public repositories. In line with journal requirements, data underlying the results in the publication may be made available to bona fide researchers for reproducibility of results. Proposals, researchers or institutions requesting data will be approved if they meet the standard criteria related to ethics, privacy and data protection regulations.

Supporting information: Study protocol, Analytic code

Time frame: Starting 6 months after publication.

Access criteria: The study data can be released to bona fide researchers by submitting a research proposal approved by a subpanel of our scientific advisory board which meets once per month with independent members to assess proposals. The data may be pseudo-anonymised or otherwise redacted to comply with the UK General Data Protection Regulation (GDPR). Researchers will be required to enter into a GDPR data sharing agreement before data may be released. Access request proposals should be sent to data.papers@joinzoe.com.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Nov 2026, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2026
First posted
Aug 24, 2026
StartActual
Aug 14, 2026
Primary completionEst.
Nov 21, 2026
CompletionEst.
Dec 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
1 added
What changed in the outcomes
  • Addedother outcomeMicrobiome compositionTime frame: Week 3 of the intervention (midpoint)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Secondary outcomes 1 added
    What changed in the outcomes
    • Addedother outcomeMicrobiome compositionTime frame: Week 3 of the intervention (midpoint)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07782593
Lead sponsor
Zoe Global Limited
Responsible party
Sponsor
First posted
Aug 24, 2026
Start date
Aug 14, 2026
Primary completion
Nov 21, 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 13, 2026

Study contacts

Study Co-ordinator
Contact
smarteats-trial@joinzoe.com
+44 (0)330 818 8669
Berry E Sarah, Professor
principal investigator · King's College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion